Louisville, Colorado-based GlobeImmune has set the initial pricing range for its IPO, saying in a regulatory filing late Tuesday that is estimating its initial public offering price to be between $15.00 and $17.00 per share. The company, which has applied to list on the NASDAQ Global Market as GBIM, is planning on offering up 2,187,500 shares of its stock in IPO. GlobeImmune is venture backed by Celgene, HealthCare Ventures, Morgenthaler Partners, Wexford-Kappa Investors, Sequel Ventures, Lilly Ventures, and Medica Venture Partners. The IPO bid for the biopharmaceuticals firm is the second, after a delay last year in its IPO efforts.
Top NewsWednesday, April 30, 2014
GlobeImmune Sets IPO Pricing Range